Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma

HER2 mutation was estimated at a frequency of approximately 8.1% in Korean patients with adenocarcinoma in the absence of known driver mutations. Because some of the HER2-mutant cases responded to poziotinib or afatinib, further studies are warranted.